The purpose of this study is to evaluate the efficacy and safety of IBI362 in Chinese patients with Type 2 Diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
252
IBI362 administered subcutaneously (SC) once a week.
placebo administered subcutaneously (SC) once a week.
Dulaglutide administered subcutaneously (SC) once a week.
China Japan Friendship Hospital
Beijing, Beijing Municipality, China
The change in HbA1c from baseline to 20 weeks
Time frame: Baseline,20 weeks
Percentage of Participants Achieving HbA1c Target of <7.0%
Time frame: Baseline,20 weeks
Number of participants with treatment-related adverse events
Time frame: Baseline,25 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.